Posterior reversible encephalopathy syndrome (PRES) is a clinical and radiological syndrome characterized by acute hypertension, headache, decreased level of consciousness, visual disturbances and seizures associated with characteristic neuroimaging changes indicative of vasogenic edema of the posterior cerebral white matter. Several medical conditions have been associated with PRES including hypertensive encephalopathy and eclampsia. The use of cytotoxic and immunosuppressant drugs, such as those which target vascular endothelial growth factor (VEGF), have also been implicated. We report here the case of a 71-year-old woman with metastatic clear cell renal carcinoma who developed PRES 3 months after commencing sorafenib. Elevated blood pressure (BP) was recorded, and MRI of the brain) of the brain showed asymmetric areas of increased signal intensity within the supratentorial white matter suggestive of PRES. Clinical and radiological features rapidly improved with BP control and discontinuation of sorafenib. Sorafenib was resumed with no sign of PRES recurrence. The present case report supports the hypothesis that, in selected patients, the re-introduction of anti-VEGF therapies after PRES is feasible.

Keywords:
Posterior reversible encephalopathy syndrome, Anti-VEGF therapies, Sorafenib, Neurological toxicity, Renal carcinoma
1.
Escudier B, et al: Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2014;25(suppl 3):iii49-iii56.
2.
Shah BK, Ghimire KB: Survival trends among patients with advanced renal cell carcinoma in the United States. Urol Int 2015;94:133-136.
3.
Hinchey J, et al: A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494-500.
4.
Tlemsani C, et al: Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Target Oncol 2011;6:253-258.
5.
Vaughn C, Zhang L, Schiff D: Reversible posterior leukoencephalopathy syndrome in cancer. Curr Oncol Rep 2008;10:86-91.
6.
Schusse CM, Peterson AL, Caplan JP: Posterior reversible encephalopathy syndrome. Psychosomatics 2013;54:205-211.
7.
Min Z, Gnann JW Jr: Reversible posterior leukoencephalopathy syndrome. Intern Emerg Med 2014;9:341-342.
8.
Hobson EV, Craven I, Blank SC: Posterior reversible encephalopathy syndrome: a truly treatable neurologic illness. Perit Dial Int 2012;32:590-594.
9.
Stevens CJ, Heran MK: The many faces of posterior reversible encephalopathy syndrome. Br J Radiol 2012;85:1566-1575.
10.
Legriel S, et al: Determinants of recovery from severe posterior reversible encephalopathy syndrome. PLoS One 2012;7:e44534.
11.
Li R, et al: Is hypertension predictive of clinical recurrence in posterior reversible encephalopathy syndrome? J Clin Neurosci 2013;20:248-252.
12.
Femia G, et al: Posterior reversible encephalopathy syndrome following chemotherapy with oxaliplatin and a fluoropyrimidine: a case report and literature review. Asia Pac J Clin Oncol 2012;8:115-122.
13.
Yoon SD, et al: Clinical and radiological spectrum of posterior reversible encephalopathy syndrome. J Cerebrovasc Endovasc Neurosurg 2013;15:206-213.
14.
Dersch R, et al: Atypical posterior reversible encephalopathy syndrome associated with chemotherapy with bevacizumab, gemcitabine and cisplatin. J Neurol 2013;260:1406-1407.
15.
Zahir MN, Masood N, Shabbir-Moosajee M: Cisplatin-induced posterior reversible encephalopathy syndrome and successful re-treatment in a patient with non-seminomatous germ cell tumor: a case report. J Med Case Rep 2012;6:409.
16.
Wilhelm SM, et al: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64:7099-7109.
17.
Rosmorduc O, et al: [Use of sorafenib in patients with hepatocellular or renal carcinoma]. Gastroenterol Clin Biol 2010;34:161-167.
18.
Govindarajan R, et al: Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006;24:e48.
19.
Dogan E, et al: Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol 2010;27:1436-1437.
20.
Asaithambi G, et al: Posterior reversible encephalopathy syndrome induced by pazopanib for renal cell carcinoma. J Clin Pharm Ther 2013;38:175-176.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.